Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Elite Pharmaceuticals's total assets was $139.67M at Jun 30, 2026. For fiscal 2026 it was $138.29M, up 43.5% from the year before. Over ten years it grew 15.9% a year on average. The highest annual figure on record is $138.29M in fiscal 2026.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $138.29M | +43.5% |
| FY2025 | Mar 31, 2025 | $96.39M | +15.2% |
| FY2024 | Mar 31, 2024 | $83.65M | +104.6% |
| FY2023 | Mar 31, 2023 | $40.90M | +16.4% |
| FY2022 | Mar 31, 2022 | $35.15M | +34.2% |
| FY2021 | Mar 31, 2021 | $26.19M | +4.9% |
| FY2020 | Mar 31, 2020 | $24.96M | +2.3% |
| FY2019 | Mar 31, 2019 | $24.40M | -21.0% |
| FY2018 | Mar 31, 2018 | $30.88M | -10.0% |
| FY2017 | Mar 31, 2017 | $34.31M | +8.3% |
| FY2016 | Mar 31, 2016 | $31.67M | +22.2% |
| FY2015 | Mar 31, 2015 | $25.92M | +6.6% |
| FY2014 | Mar 31, 2014 | $24.32M | +118.6% |
| FY2013 | Mar 31, 2013 | $11.13M | +7.9% |
| FY2012 | Mar 31, 2012 | $10.31M | -12.5% |
| FY2011 | Mar 31, 2011 | $11.79M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $139.67M | +25.4% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $138.29M | +43.5% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $126.41M | +39.3% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $117.25M | +32.9% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $111.34M | +26.7% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $96.39M | +15.2% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $90.76M | +21.5% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $88.20M | +24.7% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $87.85M | +88.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $83.65M | +104.6% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $74.70M | +41.7% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $70.72M | +40.5% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $46.50M | -3.3% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $40.90M | +16.4% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $52.72M | +65.0% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $50.34M | +64.4% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $48.11M | +60.4% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $35.15M | +34.2% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $31.95M | +11.4% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $30.62M | +10.9% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $29.99M | +7.8% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $26.19M | +4.9% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $28.67M | +19.0% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $27.61M | +17.3% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $27.82M | +14.6% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $24.96M | +2.3% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $24.09M | -8.7% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $23.53M | -13.9% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $24.28M | -14.8% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $24.40M | -21.0% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $26.38M | -17.8% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $27.32M | -14.7% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $28.50M | -15.9% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $30.88M | -10.0% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $32.07M | -11.4% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $32.01M | -8.2% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $33.89M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $34.31M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $36.20M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $34.87M | – |
See a number that looks wrong?